867 results match your criteria Expert Review of Hematology [Journal]


Brentuximab vedotin in T-cell lymphoma.

Expert Rev Hematol 2018 Dec 10. Epub 2018 Dec 10.

a Department of Haematology , Peter MacCallum Cancer Centre , Melbourne , Australia.

Introduction: Brentuximab vedotin is an antibody-drug conjugate, which combines a CD30 monoclonal antibody with the microtubule disrupting agent monomethylauristatin E. The utility of brentuximab vedotin has been explored in a number of diseases, with a recent focus on T-cell lymphoma, particularly systemic anaplastic large-cell lymphoma (sALCL) and cutaneous T-cell lymphoma (CTCL), as well as other peripheral T-cell lymphoma (PTCL) histologies. Areas covered: This review surveys current data on the efficacy of brentuximab vedotin in T-cell lymphoma, as well as embedding it in a therapeutic context by reviewing potential competitor agents in the clinic. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2019.1558399DOI Listing
December 2018
2 Reads

Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant in the USA.

Expert Rev Hematol 2018 Dec 4. Epub 2018 Dec 4.

c Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited , Cambridge , UK.

Background: Triplets with immunomodulators (IMIDs) and proteasome inhibitors (PIs) improve overall survival (OS) in trials of newly diagnosed multiple myeloma (NDMM) patients although reported outcomes in routine practice are lacking. Authors compared outcomes in NDMM patients in the USA by use of triplet vs doublet frontline therapy (FT).

Methods: This is a retrospective electronic health record database study of NDMM patients without transplant in FT between 1/1/2008 and 6/30/2017. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2019.1555460DOI Listing
December 2018
8 Reads

Measurable residual disease in acute myeloid leukemia using flowcytometry: approaches for harmonization/standardization.

Expert Rev Hematol 2018 Nov 23. Epub 2018 Nov 23.

a Department of Hematology , VU University Medical Center , De Boelelaan 1117, 1081 HV Amsterdam , Netherlands.

Introduction: Measurable Residual Disease (MRD) in acute myeloid leukemia (AML) is a rapidly evolving area with many institutes embarking on it, both in academical and pharmaceutical settings. However, there is a multitude of approaches to design, perform and report flow cytometric MRD. Together with the long-term experience needed, this makes flow cytometric MRD in AML non-standardized and time-consuming. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1549479DOI Listing
November 2018
1 Read

rFVIIIFC for hemophilia A prophylaxis.

Authors:
Johnny Mahlangu

Expert Rev Hematol 2018 Nov 19. Epub 2018 Nov 19.

a NHLS and the Charlotte Maxeke , Johannesburg academic Hospital, University of the Witwatersrand , Johannesburg , South Africa.

Introduction: rFVIIIFC was the first extended half-life product to complete the phase 3 development program and be registered. It was developed to reduce the high treatment burden imposed by prophylaxis. It is now one of four extended half-life products available for a variety of indications in hemophilia A. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1549478DOI Listing
November 2018
2 Reads

Health-related quality of life in adult primary immune thrombocytopenia.

Expert Rev Hematol 2018 Nov 16:1-11. Epub 2018 Nov 16.

a Depatment of Haematology , Odense University Hospital , Odense , Denmark.

Introduction: Immune thrombocytopenia (ITP) and the associated biologic and psychological effects can lead to reduced health-related quality of life (HRQoL). Areas covered: This review focuses on the impact of ITP itself and its treatment on patients' HRQoL. The findings show that the HRQoL is uniformly reduced amongst ITP patients, both with and without interventions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1548930DOI Listing
November 2018
4 Reads

Current strategies for hemostatic control in acute trauma hemorrhage and trauma-induced coagulopathy.

Expert Rev Hematol 2018 Nov 15:1-9. Epub 2018 Nov 15.

b Department of Traumatology and Orthopaedic Surgery, Cologne-Merheim Medical Centre (CMMC) , Witten/Herdecke University , Cologne , Germany.

Introduction: Despite advances in the treatment of severely injured patients that have resulted in overall improved outcomes, uncontrolled hemorrhage still represents the most common cause of preventable death following major injury. While addressing both endo- and exogenous factors that lead to an acute trauma-induced coagulopathy, massive transfusion plays a key role in managing bleeding trauma patients. However, the best practice for hemostatic control including massive transfusion in these patients is still under debate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1548929DOI Listing
November 2018
1 Read

Venetoclax for the treatment of multiple myeloma.

Expert Rev Hematol 2018 Nov 14. Epub 2018 Nov 14.

a Division of Hematology , Mayo Clinic , Rochester , MN , USA.

Introduction: Treatment of multiple myeloma in the relapsed setting remains challenging, despite recent impressive advances in the management of these patients. Venetoclax (ABT-199) is a BCL-2 inhibitor recently approved by the US food and drug administration (FDA) for treatment of chronic lymphocytic leukemia but the drug has shown activity in a number of hematological malignancies. Venetoclax has broadened the treatment options for patients with relapsed or refractory multiple myeloma. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1548931DOI Listing
November 2018
7 Reads

Time for patient reported outcomes assessment in routine hematology practice: the case of chronic myeloid leukemia.

Expert Rev Hematol 2018 Nov 9:1-3. Epub 2018 Nov 9.

a Data Center and Health Outcomes Research Unit , Italian Group for Adult Hematologic Diseases (GIMEMA) , Rome , Italy.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2019.1547189DOI Listing
November 2018
2 Reads

Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia.

Expert Rev Hematol 2018 Dec 8;11(12):945-956. Epub 2018 Nov 8.

a Department of Pediatric Hematology and Oncology , IRCCS, Ospedale Pediatrico Bambino Gesù , Rome , Italy.

Introduction: The clinical application of immunotherapy has resulted into a significant improvement in the outcome of children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (r/r BCP-ALL). In this setting, the use of bispecific T-cell-engager antibodies (BiTEs), such as blinatumomab, which harness the cytotoxic activity of T cells against CD19-positive lymphoblasts, has emerged as a most promising and impactful strategy. Areas covered: This review discusses the main structural and functional features of BiTEs, as well as the current status of their clinical application in childhood ALL. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1540928DOI Listing
December 2018
5 Reads

Triplet therapies - the new standard of care for multiple myeloma: how to manage common toxicities.

Expert Rev Hematol 2018 Oct 19. Epub 2018 Oct 19.

c Division of Medical Oncology, Department of Medicine , University of Washington , Seattle , WA.

Introduction: Multiple three drug combination regimens have been approved for the treatment of multiple myeloma in the last few years. Triplets have become the new standard of care for transplant eligible and ineligible patients with newly diagnosed as well as relapsed multiple myeloma. Novel agents have a unique profile of side effects. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1538777DOI Listing
October 2018
9 Reads

Optimal frontline management of mantle cell lymphoma: can we agree?

Expert Rev Hematol 2018 Oct 19:1-4. Epub 2018 Oct 19.

a Division of Medical Oncology & Hematology , Princess Margaret Cancer Centre , Toronto , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1537778DOI Listing
October 2018
1 Read

An update on treatment of higher-risk myelodysplastic syndromes.

Expert Rev Hematol 2018 Oct 18. Epub 2018 Oct 18.

a Service Hématologie Séniors, Hôpital Saint Louis , Université Paris Diderot, Assistance Publique-Hôpitaux de Paris , Paris , France.

Introduction: Myelodysplastic syndromes (MDS) are clonal stem cell disorders mostly affecting the elderly. They are classified into lower and higher risk MDS according to prognostic scoring systems. In higher-risk patients, treatments should aim to modify the disease course by avoiding progression to acute myeloid leukemia, and therefore to improve survival. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1537777DOI Listing
October 2018
7 Reads

Prognostic factors for multiple myeloma in the era of novel therapies.

Expert Rev Hematol 2018 Nov 26;11(11):863-879. Epub 2018 Oct 26.

a Department of Clinical Therapeutics, School of Medicine, "Alexandra" General Hospital , National and Kapodistrian University of Athens , Athens , Greece.

Introduction: Multiple myeloma (MM) is characterized by notable inter-patient and intra-clonal heterogeneity that is gradually decoded over the last decade. Despite the deeper and better understanding of its biology and the development of novel therapeutic strategies that have prolonged overall survival, MM still retains a poor prognosis in patient subgroups with certain high-risk features. Areas covered: This article summarizes currently identified features that stratified patients in high-risk myeloma with impaired prognosis and discusses available therapeutic options that may partially overcome the impact of these adverse factors in patients' outcome. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1537776DOI Listing
November 2018
14 Reads

Novel treatments to tackle myelofibrosis.

Expert Rev Hematol 2018 Nov 26;11(11):889-902. Epub 2018 Oct 26.

a Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai , Myeloproliferative Neoplasms Research Program , New York , NY , USA.

Introduction: Despite the dramatic progress made in the treatment of patients with myelofibrosis since the introduction of the JAK1/2 inhibitor ruxolitinib, a therapeutic option that can modify the natural history of the disease and prevent evolution to blast-phase is still lacking. Recent investigational treatments including immunomodulatory drugs and histone deacetylase inhibitors benefit some patients but these effects have proven modest at best. Several novel agents do show promising activity in preclinical studies and early-phase clinical trials. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1536538DOI Listing
November 2018
20 Reads

Andexanet alfa for the treatment of hemorrhage.

Expert Rev Hematol 2018 Nov 17;11(11):847-855. Epub 2018 Oct 17.

b Department of Pathology and Molecular Medicine, Faculty of Health Sciences , McMaster University , Hamilton , Ontario , Canada.

Introduction: While associated life-threatening and fatal bleeding events are less frequent with the direct factor Xa inhibitors compared to vitamin K antagonists, significant concern surrounding management of major bleeds and urgent periprocedural interruption of these agents exists among clinicians. Andexanet alfa is a recombinant human factor Xa decoy protein developed in response to this clinical gap in the care of patients receiving anticoagulation with factor Xa inhibitors. Areas covered: This paper reviews results from preclinical and healthy-volunteer studies demonstrating the ability of andexanet to rapidly and reliably normalize coagulation indices in patients treated with both direct and indirect factor Xa inhibitors. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1532287DOI Listing
November 2018
3 Reads

The importance of inhibitor eradication in clinically complicated hemophilia A patients.

Expert Rev Hematol 2018 Nov 4;11(11):857-862. Epub 2018 Oct 4.

f Hemophilia Center Rhein-Main - HZRM , Frankfurt - Mörfelden , Germany.

Introduction: Inhibitors against factor VIII (FVIII), which develop in around 20-30% of patients with severe hemophilia A, represent a significant complication of on-demand or prophylactic FVIII therapy. Currently, the main treatment option for inhibitor patients is eradication using immune tolerance induction (ITI) therapy. Areas covered: This article reviews inhibitor eradication in clinically complicated hemophilia A patients. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1521718DOI Listing
November 2018
6 Reads

Management of multiple myeloma bone disease: impact of treatment on renal function.

Expert Rev Hematol 2018 Nov 20;11(11):881-888. Epub 2018 Oct 20.

a Department of Clinical Therapeutics , National and Kapodistrian University of Athens School of Medicine, Alexandra General Hospital , Athens , Greece.

Introduction: Bone disease (BD) is one of the most common features of multiple myeloma. Seventy to eighty percent of patients at diagnosis present with lytic lesions which may lead to skeletal-related events. Areas covered: The aim of this review is to present the possible adverse profile of bisphosphonates (BPs) on renal function, the underlying mechanisms by which BPs may affect renal function and the novel therapeutic approaches on myeloma bone disease management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1531702DOI Listing
November 2018
3 Reads

Emicizumab for hemophilia A with factor VIII inhibitors.

Expert Rev Hematol 2018 Nov 10;11(11):835-846. Epub 2018 Oct 10.

f Department of Pediatrics , University of Michigan , Ann Arbor , MI , USA.

Introduction: Hemophilia is a serious bleeding disorder characterized by repeated bleeding episodes into joints and muscles which can lead to permanent disabilities. Treatment with factor replacement therapy has proven to be effective at preventing these complications; however, it can lead to formation of neutralizing antibodies termed inhibitors which significantly complicate the management of the disorder. These inhibitor patients suffer from increased morbidity and mortality and there has been a major unmet need for novel therapeutic approaches. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1531701DOI Listing
November 2018
10 Reads

The prevention of venous thromboembolism recurrence in the elderly: a still open issue.

Expert Rev Hematol 2018 Nov 26;11(11):903-909. Epub 2018 Sep 26.

b Thrombosis Centre , Azienda Ospedaliero-Universitaria Careggi , Florence , Italy.

Introduction: Venous thromboembolism (VTE) is frequent in the elderly, with an unclear recurrence risk. After the initial and early maintenance anticoagulant treatment, the decision about its extension versus recurrences is difficult because of the high risk of bleeding in this population. Areas covered: This paper analyzes recent literature on VTE recurrence and risk of bleeding associated with extended anticoagulation in elderly patients with VTE, focusing on available data regarding efficacy and safety of old anticoagulant or recent direct oral anticoagulant (DOACs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1526667DOI Listing
November 2018
5 Reads

Ferumoxytol for the treatment of iron deficiency anemia.

Expert Rev Hematol 2018 Oct 14;11(10):829-834. Epub 2018 Sep 14.

c Department of Medicine , University of Virigina Health System , Charlottesville , Virignia , USA.

Introduction: Ferumoxytol is a superparamagnetic molecule originally developed as a contrast agent for magnetic resonance imaging. Elemental iron is contained within the carbohydrate core and is released slowly after infusion allowing a large dose of iron to be administered in a short period of time. Ferumoxytol, originally approved for iron deficiency in chronic kidney disease, received a broad label for any cause of iron deficiency after oral iron intolerance or in those circumstances when oral iron is ineffective or harmful. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1518712DOI Listing
October 2018
9 Reads

Ixazomib: a novel drug for multiple myeloma.

Expert Rev Hematol 2018 Oct;11(10):761-771

a Division of Hematology , Mayo Clinic , Rochester , MN , USA.

Introduction: Proteasome inhibitors (PIs) have been an integral part of treatment for multiple myeloma (MM) over the past decade. Many newer PIs are being evaluated in pre-clinical and clinical setting, with an aim to improve the safety, efficacy and resistance profile of this class of drugs. Ixazomib is the first oral PI with a robust efficacy and favorable safety profile in MM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1518129DOI Listing
October 2018
17 Reads

Anticoagulation at the extremes of body weight: choices and dosing.

Expert Rev Hematol 2018 Oct 25;11(10):817-828. Epub 2018 Sep 25.

d Department of Clinical Haematology , Westmead Hospital , Westmead , Australia.

Introduction: The landscape of therapeutic anticoagulation has changed dramatically over the past decade, with availability of direct oral anticoagulants (DOACs), which inhibit factor Xa or thrombin. However, the optimal anticoagulant agent and dosing strategy for patients at both extremes of body weight has not been established for any anticoagulant, including DOACs, vitamin K antagonists (VKA), and the various heparin options. Areas covered: This paper reviews available evidence to assist clinicians in prescribing of anticoagulation therapy at the extremes of body weight. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1517040DOI Listing
October 2018
23 Reads

The potential role of miRNAs in multiple myeloma therapy.

Expert Rev Hematol 2018 Oct 12;11(10):793-803. Epub 2018 Sep 12.

a Department of Experimental and Clinical Medicine , Magna Græcia University, Campus Salvatore Venuta , Catanzaro , Italy.

Introduction: MicroRNAs (miRNAs) are short non-coding RNAs that are crucial players as post-transcriptional regulators of messenger RNAs (mRNAs). miRNA deregulation has been associated to the pathogenesis of several human malignancies, since they might potentially regulate relevant pathways involved in cancer onset and progression. Therefore, targeting the miRNA network could represent a promising therapeutic strategy for human cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1517041DOI Listing
October 2018
1 Read

Determining the sequence of novel therapies in the treatment of relapsed Hodgkin's lymphoma.

Expert Rev Hematol 2018 Oct 5;11(10):773-780. Epub 2018 Sep 5.

a Lombardi Comprehensive Cancer Center , MedStar Georgetown University Hospital , Washington , DC , USA.

Introduction: Hodgkin's lymphoma (HL) accounts for about 10% of all lymphomas in the U.S.A. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1516135DOI Listing
October 2018
9 Reads

Comorbidities, age, and other patient-related predictors of allogeneic hematopoietic cell transplantation outcomes.

Expert Rev Hematol 2018 Oct 16;11(10):805-816. Epub 2018 Aug 16.

a Clinical Research Division , Fred Hutchinson Cancer Research Center , Seattle , WA , USA.

Introduction: Allogeneic hematopoietic cell transplantation (HCT) provides potential cure to a large number of malignant and nonmalignant hematological disorders. With the development of non-myeloablative and reduced-intensity conditioning regimens, allogeneic HCT can nowadays be offered to a number of older or medically unfit patients. Up until the twenty-first century, chronological age was considered a hypothetical barrier. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1509703DOI Listing
October 2018

Advances in the genetics of acute lymphoblastic leukemia in adults and the potential clinical implications.

Expert Rev Hematol 2018 Oct 16;11(10):781-791. Epub 2018 Aug 16.

a Department of Hematology and Bone Marrow Transplantation , Rambam Health Care Campus , Haifa , Israel.

Introduction: Acute lymphoblastic leukemia (ALL) is a clonal disease of the hematopoietic system characterized by unique genetic characteristics. The significance of these genetic features has evolved over the past three decades. In the 1980s and 1990s, the primary interest was in excluding the Philadelphia chromosome; a finding more common in older adults which uniformly predicted for a rapidly fatal outcome. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1509702DOI Listing
October 2018
8 Reads

Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy.

Expert Rev Hematol 2018 Sep 14;11(9):697-706. Epub 2018 Aug 14.

a University Clinic for Haematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, UKRUB, University of Bochum , Minden , Germany.

Introduction: The management of pregnancy during the course of BCR-ABL1-negative myeloproliferative neoplasms (MPN) is an increasingly relevant problem. This is mostly due to earlier and better diagnosis of MPN together with the trend in modern society toward delaying pregnancy until later life. Areas Covered: The present review aims to provide an overview of the available literature data concerning outcome of pregnancy in MPN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1506325DOI Listing
September 2018
12 Reads

Non-Hodgkin's lymphoma of the oral cavity and maxillofacial region: a pathologist viewpoint.

Expert Rev Hematol 2018 Sep 21;11(9):737-748. Epub 2018 Aug 21.

a Department of Pathology , Assiut University Hospitals , Assiut , Egypt.

Introduction: Non-Hodgkin lymphomas of the oral and maxillofacial regions are uncommon malignancies. They usually have progressive course and dismal outcome. Areas covered: This review provides an update about the clinicopathologic, immunophenotypic, and molecular features of these lymphomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1506326DOI Listing
September 2018
6 Reads

New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?

Expert Rev Hematol 2018 Sep 2;11(9):749-756. Epub 2018 Aug 2.

b Department of Hematology and Hematopoietic Cell Transplantation , City of Hope National Medical Center , Duarte , CA , USA.

Introduction: Despite recent prognostic improvements, mantle cell lymphoma (MCL) remains incurable. Bruton tyrosine kinase (BTK) is a key receptor in B-cell tumorigenesis, and the benefits of the first BTK inhibitor, ibrutinib, are becoming clear in MCL. However, off-target activities, which contribute to ibrutinib-related adverse events, suggest potential for further improvement of this drug class. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1506327DOI Listing
September 2018
1 Read

Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place.

Expert Rev Hematol 2018 Sep 22;11(9):715-726. Epub 2018 Aug 22.

a Division of Hematology/Medical Oncology, Department of Medicine , Yale University School of Medicine , New Haven , USA.

Introduction: Myelodysplastic syndromes (MDS) encompass a heterogenous collection of clonal hematopoietic stem cell disorders defined by dysregulated hematopoiesis, peripheral cytopenias, and a risk of leukemic progression. Increasing data support the role of innate and adaptive immune pathways in the pathogenesis and disease course of MDS. The role of immunosuppressive therapy has an established role in the treatment of other hematologic diseases, such as aplastic anemia whose pathogenesis is postulated to reflect that of MDS with regards to many aspects of immune activation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1503049DOI Listing
September 2018
12 Reads

Impact and management of iron deficiency and iron deficiency anemia in women's health.

Expert Rev Hematol 2018 Sep 1;11(9):727-736. Epub 2018 Aug 1.

g Department of Internal Medicine , American University of Beirut Medical Center , Beirut , Lebanon.

Introduction: Iron deficiency and iron deficiency anemia are highly prevalent among women throughout their lives. Some females are particularly vulnerable to iron deficiency/iron deficiency anemia, including those with heavy menstrual bleeding (HMB) and pregnant/postpartum women. Despite the high prevalence of iron deficiency/iron deficiency anemia in women, the condition is still underdiagnosed and therefore undertreated, with serious clinical consequences. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1502081DOI Listing
September 2018
15 Reads

Management and treatment of deep vein thrombosis in special populations.

Expert Rev Hematol 2018 09 25;11(9):685-695. Epub 2018 Jul 25.

a Department of Thrombosis and Hemostasis , Leiden University Medical Center , Leiden , The Netherlands.

Introduction: Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most frequent cardiovascular disease besides myocardial infarction and stroke. Because DVT may cause life-threatening conditions, treatment should be started as soon as possible. This comprises certain challenges in special populations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1502082DOI Listing
September 2018
1 Read

Chronic myeloid leukemia and pregnancy: patient and partner perspectives.

Authors:
Marlise R Luskin

Expert Rev Hematol 2018 Aug 23;11(8):597-599. Epub 2018 Jul 23.

a Department of Medical Oncology , Dana-Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1500889DOI Listing

Pacritinib to treat myelofibrosis patients with thrombocytopenia.

Expert Rev Hematol 2018 Sep 19;11(9):707-714. Epub 2018 Jul 19.

a Icahn School of Medicine at Mount Sinai , Tisch Cancer Institute , New York , NY , USA.

Introduction: Treatment with ruxolitinib, a selective JAK1/2 inhibitor, has significantly improved the lives of patients with myelofibrosis. Unfortunately, this treatment is frequently limited by cytopenias, precluding a high-risk group characterized by baseline thrombocytopenia. Additionally, there are no approved treatments for patients who have progressed while receiving ruxolitinib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1500456DOI Listing
September 2018
4 Reads

Disseminated intravascular coagulation: an update on pathogenesis and diagnosis.

Expert Rev Hematol 2018 Aug 20;11(8):663-672. Epub 2018 Jul 20.

c Department of Immunobiology , Queen Mary University of London , London , United Kingdom.

Introduction: Activation of the hemostatic system can occur in many clinical conditions. However, a systemic and strong activation of coagulation complicating clinical settings such as sepsis, trauma or malignant disease may result in the occurrence disseminated intravascular coagulation (DIC). Areas covered: This article reviews the clinical manifestation and relevance of DIC, the various conditions that may precipitate DIC and the pathogenetic pathways underlying the derangement of the hemostatic system, based on clinical and experimental studies. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1500173DOI Listing
August 2018
10 Reads

Advances in pathological understanding of high-grade B cell lymphomas.

Expert Rev Hematol 2018 Aug 10;11(8):637-648. Epub 2018 Jul 10.

a Department of Hematopathology , The University of Texas MD Anderson Cancer Center , Houston , Texas , USA.

Introduction: The designation high-grade B-cell lymphoma (HGBL) has been incorporated into the 2016 Revision of the WHO classification of lymphoid neoplasms and includes two types: (1) HGBL, not otherwise specified; and (2) HGBL with MYC and BCL2 and/or BCL6 rearrangements, also known as double or triple hit lymphoma (DHL/THL). These categories of lymphomas represent 1-2% of non-Hodgkin lymphomas and a considerable portion of DLBCL patients who are primary refractory to R-CHOP therapy. It corresponds to the designation 'B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma' in the 2008 WHO classification. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1494567DOI Listing
August 2018
5 Reads

Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia.

Expert Rev Hematol 2018 Aug 18;11(8):601-611. Epub 2018 Jul 18.

a Hematology, Department of Cellular Biotechnologies and Hematology , Sapienza University and Policlinico Umberto 1 , Rome , Italy.

Introduction: In recent years, innovative mechanism-based drugs have enriched the therapeutic armamentarium for patients with chronic lymphocytic leukemia (CLL) and are widely used in the clinical practice. These small molecules targeting the B-cell receptor signaling pathway and the BCL-2 anti-apoptotic protein offer new chemo-free options to both unfit patients and high-risk patients who show a poor response to chemoimmunotherapy. Nonetheless, treatment with ibrutinib, idelalisib and venetoclax is associated with unique side effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1495557DOI Listing
August 2018
9 Reads

Germ line predisposition to myeloid malignancies appearing in adulthood.

Expert Rev Hematol 2018 Aug 23;11(8):625-636. Epub 2018 Jul 23.

a Medical Faculty, Dept. of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation , University Hospital RWTH Aachen , Aachen , Germany.

Introduction: Germ line predisposition to myeloid neoplasms has been incorporated in the WHO 2016 classification of myeloid neoplasms and acute leukemia. The new category of disease is named hereditary myeloid disorder (HMD). Although most myeloid neoplasms are sporadic, germ line mutations and familial predisposition can contribute to development of chronic myeloid diseases and acute myeloid leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1494566DOI Listing
August 2018
11 Reads

Maintaining therapeutic progress in multiple myeloma by integrating genetic and biological advances into the clinic.

Expert Rev Hematol 2018 Jul 26;11(7):513-523. Epub 2018 Jun 26.

a Myeloma Institute , The University of Arkansas for Medical Sciences , Little Rock , AR , USA.

Introduction: Utilizing advances in genetic and immunologic analysis to segment and direct treatment is potentially a way of maintaining therapeutic progress toward cure in multiple myeloma (MM). This approach works well using clinical segments but can be optimized using recent genetic and immunologic technologies, which have opened the possibility of enhancing risk stratification and disease subclassification. Areas covered: This position paper discusses strategies to segment myeloma into subgroups with distinct risk profiles and distinct targetable lesions are presented. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1489718DOI Listing

Autoimmune cytopenias in chronic lymphocytic leukemia: a concise review and treatment recommendations.

Expert Rev Hematol 2018 Aug 14;11(8):613-624. Epub 2018 Jul 14.

a Department of Hematology and Lymphoma and Myeloma Center (LYMMCARE) , Academic Medical Center, University of Amsterdam , Amsterdam , The Netherlands.

Introduction: Chronic lymphocytic leukemia (CLL) is frequently complicated by cytopenias, either due to bone marrow infiltration or autoimmunity, resulting in autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), pure red cell aplasia (PRCA), or autoimmune neutropenia (AIN). Morbidity due to autoimmune cytopenias (AIC) can be substantial; in addition, infection risk increases and pre-existing infections might deteriorate due to immunosuppressive medication. In the aging population, CLL occurs more frequently and AIC related to CLL represent a growing clinical challenge. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1489720DOI Listing
August 2018
7 Reads

Pixantrone: novel mode of action and clinical readouts.

Expert Rev Hematol 2018 Jul 18;11(7):587-596. Epub 2018 Jun 18.

d Istituto Oncologico di Ricerca , Università della Svizzera italiana , Bellinzona , Switzerland.

Introduction: Pixantrone is a first-in-class aza-anthracenedione approved as monotherapy for treatment of relapsed or refractory aggressive diffuse B-cell non-Hodgkin's lymphoma (NHL), a patient group which is notoriously difficult to treat. It has a unique chemical structure and pharmacologic properties distinguishing it from anthracyclines and anthracenediones. Areas covered: The chemical structure and mode of action of pixantrone versus doxorubicin and mitoxantrone; preclinical evidence for pixantrone's therapeutic effect and cardiac tolerability; efficacy and safety of pixantrone in clinical trials; ongoing and completed trials of pixantrone alone or as combination therapy; and the risk of cardiotoxicity of pixantrone versus doxorubicin and mitoxantrone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1476848DOI Listing
July 2018
20 Reads

The benefits of prophylaxis in patients with hemophilia B.

Expert Rev Hematol 2018 Aug 18;11(8):673-683. Epub 2018 Jul 18.

a Center for Bleeding Disorders , Careggi University Hospital , Florence , Italy.

Introduction: The health benefits of prophylactic dosing regimens for clotting factor therapy in patients with hemophilia include reduced joint damage and improved quality of life; as such, prophylaxis is recommended in treatment guidelines. However, many patients with hemophilia B are treated on demand, and prophylaxis has been utilized less frequently than in hemophilia A. Areas covered: This review discusses the opportunities and evidence for prophylaxis in hemophilia B, in the context of treatment guidelines and with regard to factor IX (FIX) replacement therapies, including long-acting recombinant FIX (rFIX). Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1489719DOI Listing
August 2018
4 Reads

Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy.

Expert Rev Hematol 2018 Jul 19;11(7):577-586. Epub 2018 Jun 19.

b Malignant Hematology Department , Moffitt Cancer Center , Tampa , FL , USA.

Introduction: Patients with myelodysplastic syndromes (MDS) are at increased risk of iron overload due to ineffective erythropoiesis and chronic transfusion therapy. The clinical consequences of iron overload include cardiac and/or hepatic failure, endocrinopathies, and infection risk. Areas covered: Iron chelation therapy (ICT) can help remove excess iron and ultimately reduce the clinical consequences of iron overload. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1486188DOI Listing
July 2018
7 Reads

Prophylactic versus on-demand treatments for hemophilia: advantages and drawbacks.

Expert Rev Hematol 2018 Jul 19;11(7):567-576. Epub 2018 Jun 19.

a Center for Bleeding Disorders and Coagulation, Department of Oncology , Careggi University Hospital , Florence , Italy.

Introduction: Early long-term prophylaxis is the standard of care to prevent joint bleeding and chronic arthropathy in patients with severe hemophilia. Areas covered: Despite the obvious prophylaxis advantages upon the clinical outcomes, there are still several drawbacks to be addressed for the optimal patients' compliance. Frequency of treatment due to short half-life of conventional FVIII and FIX concentrates, difficult venous access, adherence to the prescribed therapy and costs may represent significant critical issues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1486704DOI Listing

Stem cell transplantation in sickle cell disease: therapeutic potential and challenges faced.

Expert Rev Hematol 2018 Jul 20;11(7):547-565. Epub 2018 Jun 20.

a Molecular and Clinical Hematology Branch, National Heart, Lung, and Blood Institute , National Institutes of Health , Bethesda , MD , USA.

Introduction: Sickle cell disease (SCD) is the most common inherited hemoglobinopathy worldwide, and is a life-limiting disease with limited therapeutic options to reduce disease severity. Despite being a monogenic disorder, the clinical phenotypes of SCD are variable, with few reliable predictors of disease severity easily identifying patients where the benefits of curative therapy outweigh the risks. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative option, though significant advances in gene therapy raise the promise for additional curative methods. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1486703DOI Listing

Diagnosis and management of prefibrotic myelofibrosis.

Expert Rev Hematol 2018 Jul 22;11(7):537-545. Epub 2018 Jun 22.

a Department of Molecular Medicine , University of Pavia , Pavia , Italy.

Introduction: The 2016 WHO classification comprises two stages of primary myelofibrosis (PMF): early/prefibrotic primary myelofibrosis (pre-PMF) and overt fibrotic PMF (overt PMF). Diagnostic criteria rely on bone marrow morphology, fibrosis grade (0-1 in pre-PMF, 2-3 in overt PMF), and clinical features (leukoerythroblastosis, anemia, leucocytosis, increased lactate dehydrogenase, and palpable splenomegaly). An accurate differentiation from essential thrombocythemia (ET) is pivotal because the two entities show different clinical presentation and outcome, in terms of survival, leukemic evolution, and rates of progression to overt myelofibrosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1484280DOI Listing
July 2018
5 Reads

Incorporating placental tissue in cord blood banking for stem cell transplantation.

Expert Rev Hematol 2018 Aug 14;11(8):649-661. Epub 2018 Jul 14.

b Centro di Ricerca "E. Menni" Fondazione Poliambulanza - Istituto Ospedaliero , Brescia , Italy.

Introduction: Human term placenta is comprised of various tissues from which different cells can be obtained, including hematopoietic stem cells and mesenchymal stem/stromal cells (MSCs). Areas covered: This review will discuss the possibility to incorporate placental tissue cells in cord blood banking. It will discuss general features of human placenta, with a brief review of the immune cells at the fetal-maternal interface and the different cell populations isolated from placenta, with a particular focus on MSCs. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1483717DOI Listing
August 2018
4 Reads

Cellular immunotherapy as a therapeutic approach in multiple myeloma.

Expert Rev Hematol 2018 Jul;11(7):525-536

a Department of Medicine , Beth Israel Deaconess Medical Center, Harvard Medical School , Boston , MA , USA.

Introduction: Immunotherapy seeks to restore and augment the unique ability of the immune system to recognize and kill malignant cells. This strategy has previously been incorporated into standard of care in myeloma with the use of immunomodulatory drugs and allogeneic transplant. The following review will discuss the rationale for immunotherapy to reverse critical aspects of the immunosuppressive milieu in myeloma and avenues where cellular therapies are now revolutionizing myeloma treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1483718DOI Listing

Genetic profiling in acute myeloid leukemia: a path to predicting treatment outcome.

Expert Rev Hematol 2018 Jun 24;11(6):455-461. Epub 2018 May 24.

b Department of Experimental, Diagnostic, and Specialty Medicine, S. Orsola-Malpighi Hospital , Bologna University School of Medicine , Bologna , Italy.

Introduction: Despite substantial progresses in acute myeloid leukemia (AML) diagnosis and treatment, at least half of patient will eventually die for the disease. In the last decades, the use of genetic and genomic approaches allowed the identification of patients with higher risk of recurrence after and/or resistance to CHT. However, though many novel drugs have been proposed and tested, only little clinical improvements have been made concerning the treatment of the so called 'high risk' patients. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1475225DOI Listing
June 2018
9 Reads